The European Medicines Agency has started reviewing a new batch of medicines for potential pan-EU marketing approval.

Advanz and Alvotech have struck a deal that will give Advanz exclusive rights to the biosimilars developer’s Xolair (omalizumab) rival in multiple markets around the world.

The latest Generics Bulletin Top 50 ranking of global generics and biosimilars companies sees a new name in the top five amid transformations for some of the leading off-patent players. Meanwhile, a number of mid-level firms shift position and newcomers climb into the bottom of the table.

Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.